Sanofi, a healthcare company, is engaged in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. The company is headquartered in Paris, France.
| Revenue (TTM) | $50.98B |
| Gross Profit (TTM) | $37.57B |
| EBITDA | $14.47B |
| Operating Margin | 30.90% |
| Return on Equity | 5.72% |
| Return on Assets | 5.31% |
| Revenue/Share (TTM) | $21.18 |
| Book Value | $34.11 |
| Price-to-Book | 1.40 |
| Price-to-Sales (TTM) | 2.21 |
| EV/Revenue | 2.249 |
| EV/EBITDA | 12.69 |
| Quarterly Earnings Growth (YoY) | 9.40% |
| Quarterly Revenue Growth (YoY) | 15.70% |
| Shares Outstanding | $2.40B |
| Float | $2.16B |
| % Insiders | 0.00% |
| % Institutions | 8.05% |
Volatility is currently contracting
Sanofi NASDAQ: SNY reported third-quarter 2026 sales growth of 14.3% at constant exchange rates, supported by continued demand for Dupixent, recently launched medicines and growth in rare diseases. The company also raised its full-year sales and business EPS outlook while outlining a strategy focused on immunology, rare diseases and vaccines.
A strong third quarter has made Regeneron Pharmaceuticals (NASDAQ:REGN | REGN Price Prediction) a standout healthcare gainer on a day when tech stocks are selling off. In morning trading, Regeneron stock has climbed to $919.58, up 12%.
SNY beats Q3 earnings and sales estimates as Dupixent drives growth and the company raises its 2026 outlook for sales and business EPS.
The French drugmaker is moving to fill its medicine pipeline to prepare for the looming patent expiration of its bestselling product, Dupixent.
Sanofi has increased its dividend for 31 consecutive years. It's only because this is not an American company in the S&P 500 that it's not a dividend aristocrat. Sanofi increased its revenue from €34.7 billion in FY 2016 to €43.6 billion in FY 2025. That's a compound annual growth rate of 2.6%. Sanofi has a great financial position. The long-term debt/equity ratio is 0.2, while the interest coverage ratio is 11.
Sanofi is deeply undervalued, trading at 8.4x P/E despite AA rating, robust balance sheet, and a 5.8% dividend yield. I see SNY pipeline risks as overstated; Dupixent's expansion and multiple smaller launches provide solid growth through 2028E. Even with no new blockbusters, SNY offers 15%+ annualized upside at normalized EPS and historical multiples, supporting a strong value thesis.
Sanofi's CirCLIQ® Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of-care regimens, for patients with multiple myeloma Sanofi's CirCLIQ® Injector, developed using enFuse technology, has been approved to administer Sarclisa subcutaneous formulation, in combination with approved standard-of-care regimens, for patients with multiple myeloma
Sanofi breaks ground on new state-of-the-art insulin manufacturing facility in Germany Paris and Frankfurt, October 19, 2 026. Sanofi today broke ground on a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany.
Sanofi's upgraded 2026 outlook, Dupixent growth and attractive valuation give it an edge over AbbVie, despite pipeline setbacks and vaccine sales challenges.
Availability of the aide-mémoire for Q3 2026 results Paris, France – October 6, 2026. Sanofi announced today the availability of the aide-mémoire for Q3 2026 results on the "Investors" page of sanofi.com: Third quarter 2026 results Prepared each quarter, this document is intended to support financial modelling of the quarterly results.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on SNY and any ticker you trade — then tracks every position and per-strategy win rate.
